News

A bill designed to provide assistance to patients who cannot afford their insulin was signed into law by Minnesota Governor Tim Walz.

A percentage of oncology pharmacy practitioners report their guidance on biosimilars is influential with clinicians, but many feel their knowledge of biosimilars is deficient in a number of important areas.

A commentary in The Lancet suggests that the new biological pathway for insulin product approval, established in March, will be insufficient to address issues insulin prices and biosimilar uptake.

The private payer lobby America’s Health Insurance Plans has issued a laundry list of things the FDA and Federal Trade Commission could do to improve biosimilar access.

In partnership with Samsung Bioepis, Merck has launched the trastuzumab biosimilar Ontruzant, which marks the fifth trastuzumab biosimilar available on the US market.

The Boston Medical Center Health System (BMCHS) of Massachusetts was able to achieve high adoption rates for biosimilars based on experience with a “nonbiosimilar.”

After noting the stories of individuals with diabetes dying due to their inability to afford insulin, the Minnesota House has passed an emergency insulin bill that is expected to move rapidly through the Senate to the governor’s desk.

The first 3 months of 2019 saw a trio of biosimilar launches on the US market, ahead of the year-ago quarter's pace, and this came despite the disruption caused by coronavirus disease 2019.

With the launch of Mylan and Biocon’s pegfilgrastim biosimilar, Australia adds another biosimilar to its portfolio of biosimilars in circulation.

The introduction of biosimilars as anticancer therapies was preceded by a period of supportive care biosimilars. Lee S. Schwartzberg, MD, FACP, describes how he and other clinicians decide which of these agents to use.

Cancer treatments can lead to unpredictable adverse events, so a COVID-19–related measure allowing home infusion jeopardizes patient health and safety, according to the Community Oncology Alliance (COA).

The World Health Organization’s guidance for the development and approval of biosimilars is based on faulty science and reasoning, and it represents a hazard to the safety of patients that must be corrected, according to Sarfaraz K. Niazi, PhD.

The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.

The Center for Biosimilars® recaps the top stories for the week of April 6, 2020.

Oncologist/hematologist Lee S. Schwartzberg, MD, FACP, describes some important considerations for using biosimilars in clinical practice.

With positive phase 1 study results and a manufacturing process that may cut costs significantly, BiosanaPharma hopes its omalizumab biosimilar candidate will have an edge on the worldwide market.

Biosimilar companies may do themselves a disservice if they produce education materials that don’t address the needs of clinicians or blatently self-promote, according to Kathy Oubre, chief operations officer at Pontchartrain Cancer Center of Louisiana.

The FDA’s new focus on coronavirus disease 2019 (COVID-19) and the quarantines imposed on much of the developed world have pushed digital and remote marketing of pharmaceutical products into high gear, according to Jamie Peck, managing director of iON.

NeuClone said phase 1 patient monitoring and blood sampling has been completed for its ustekinumab biosimilar candidate, which is targeted at the $6.6 billion in annual revenue earned by Stelara, a Janssen Pharmaceutical Companies product.

Longtime generics manufacturer Lannett is moving an insulin glargine biosimilar development plan forward and announced an upcoming meeting with the FDA. The agent would compete with the reference product Lantus.

Because they will see greater savings, employers have greater incentive to embrace biosimilars than plan sponsors in the overall insured population. Employers can be advocates for policy changes that promote biosimilars by contacting legislators; they can organize email campaigns to reach lawmakers more easily.

There are multiple distinctions in labeling indications between biosimilars and brand products, and pharmacists must become familiar with these to be of maximum service to patients and physicians, according to a review.

The National Comprehensive Cancer Network (NCCN) Guidelines may help get biosimilars into circulation because the NCCN will recommend them for off-label uses.

In inflammatory bowel diseases (IBD), biosimilars have been available for roughly 5 years, but more evidence may be necessary to persuade medical community to increase usage, according to a study.

Trade groups and consumer advocates are working to fight the rising tide of protectionism generated by the coronavirus disease 2019 pandemic. The International Generic and Biosimilar Medicines Association (IGBA) is calling for dedicated air and sea channels to keep pipelines of essential medicines open between borders.

What is ahead for biosimilar litigation? We highlight a recent interview Goodwin partners gave recently about their new guide to biosimilar litigation.

Providence St. Joseph Health used Toyota’s Kaizen system of nonvariance and standardization to build a model that increased use of biosimilars among physicians. The model employed the electronic health record system to guide physicians toward use of biosimilars, thereby increasing savings.

The Center for Biosimilars® recaps the top stories for the week of March 30, 2020.

MJH Life Sciences™, owner of The Center for Biosimilars®, has acquired the Pharmacy Benefit Management Institute (PBMI), the nation’s leading provider of research and education that informs, advises, and influences the industry on drug cost management.

The race to find a way to knock down the coronavirus disease 2019 pandemic has attracted companies with stakes in the biosimilar game. The winner could take all.